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ABBREVIATIONS 
CNS: Central nervous system
CV: Coefficient of variation
CYP: Cytochrome P450
E2: Estradiol
EDC: Endocrine disrupting chemical
FSH: Follicle stimulating hormone
GnRH: Gonadotropin-releasing hormone
LH: Luteinizing hormone
P4: Progesterone
PK: Pharmacokinetics
QSAR: Quantitative structure-activity relationship
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ABSTRACT
Background:  Combining computational toxicology with ExpoCast exposure estimates and
ToxCast assay  data  gives  us  access  to  predictions  of  human health  risks  stemming from
exposures to chemical mixtures.
Objectives: To explore, through mathematical modeling and simulations, the size of potential
effects of random mixtures of aromatase inhibitors on  the dynamics of women's menstrual
cycles.
Methods: We simulated random exposures to millions of potential mixtures of 86 aromatase
inhibitors. A pharmacokinetic model of intake and disposition of the chemicals predicted their
internal concentration as a function of time (up to two years). A ToxCast aromatase assay
provided  concentration-inhibition  relationships  for  each  chemical.  The  resulting  total
aromatase  inhibition  was input  to  a  mathematical  model  of  the  hormonal  hypothalamus-
pituitary-ovarian control of ovulation in women.
Results:  Above  10% inhibition  of  estradiol  synthesis  by  aromatase  inhibitors,  noticeable
(eventually reversible) effects on ovulation were predicted. Exposures to individual chemicals
never  led  to  such  effects.  In  our  best  estimate,  about 10%  of  the  combined  exposures
simulated had  mild  to  catastrophic  impacts  on  ovulation.  A lower  bound  on  that  figure,
obtained using an optimistic exposure scenario, was 0.3%.
Conclusions:  These results demonstrate the possibility to predict large-scale mixture effects
for endocrine disrupters with a predictive toxicology approach, suitable for high-throughput
ranking and risk assessment.  The size of the effects predicted is consistent with an increased
risk of infertility in women from everyday exposures to our chemical environment.
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INTRODUCTION
Concern is growing worldwide over the negative human health and environmental impacts of
chemical pollutants that can interfere with the production, metabolism, and action of natural
hormones, the so-called endocrine-disrupting chemicals (EDCs). In humans, EDCs have been
linked to reproductive disorders (Sweeney et al. 2015), abnormal or delayed development in
children (Schug et al. 2015), and changes in immune function (Rogers et al. 2013) or cancer
(Birnbaum and Fenton 2002).  Exposure to mixtures of EDCs may result in effects that can
depart from mere summation (Kortenkamp 2007), and human subgroups (e.g., women) may
not  be  sufficiently  protected  against  mixtures  of  EDCs  by  current  regulatory  limits
(Kortenkamp 2014).
Each  menstrual  cycle  in  women  involves  hormonal  regulation  of  follicular  growth  and
maturation resulting in ovulation of a  single oocyte (Falcone and Hurd 2013). The cycle is
controlled  by  coordinated  stimulations  and  inhibitions  along  the  hypothalamus-pituitary-
ovarian axis. GnRH, secreted by the hypothalamus, stimulates the secretion of gonadotropins
(FSH and LH) by the anterior pituitary gland. Those in turn regulate the secretion of ovarian
hormones,  such  as  estradiol  (E2)  or  progesterone  (P4).  Exposures  to  EDCs interfering
directly or indirectly with any of these hormones can eventually induce infertility or other
pathological outcomes.  Aromatase is critical because it irreversibly converts testosterone to
E2 and androstenedione to estrone, maintaining the dynamic balance between androgens and
estrogens. 
The objective of the current work is to explore predictively the effects of exposure to large
scale  (i.e.,  potentially  real-life)  mixtures  of  aromatase  inhibitors  on  the  dynamics  of
menstrual cycling in women. We input exposure estimates from ExpoCast (Wambaugh et al.
2013) and biological effect data from ToxCast (Dix et al. 2007) to coupled pharmacokinetic
(PK)  and  ovarian  cycle models.  This  provided  a  quantitative  mechanistic  link  between
exposure to mixtures of EDCs and their potential  adverse effects on the menstrual cycle in
women.  We  compared  the  expected  effects  of  exposures  to  single  EDCs,  as  usually
considered  by risk  assessment  provisions  in  different  regulations,  to  estimated  effects  of
cumulative and concurrent exposures.
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METHODS
Workflow overview
The  overall  computational  workflow is  pictured  on  Figure  S1 in  Supplemental  Material.
Briefly, after selecting the chemicals of interest, we sampled millions of random mixtures of
chemicals using the exposure estimates provided by ExpoCast (Wambaugh et al. 2013). Both
constant  and  time-varying  exposure  scenarios  of  an  adult  woman  were  considered.  A
pharmacokinetic  model  of  intake  and  disposition  was  then  used  to  estimate  the  blood
concentration  (over  two years)  for  each  chemical  present  in  each mixture.  The  resulting
aromatase activity inhibition was estimated using the Hill's dose-response model parameters
provided by ToxCast (Dix et al. 2007). A mathematical model of the hypothalamus-pituitary-
ovarian hormonal events  (based on Chen and Ward 2013) was used to  predict the levels of
E2,  P4,  and  other  quantities  characterizing  the  ovarian  cycle,  for  a  reference  cycle  and
following exposure to the mixtures generated. Monte Carlo sampling (Bois et al. 2010) was
used to propagate uncertainties in exposure, kinetics, and dose-response relationships up to
ovarian cycle perturbation.
Databases, chemical selection, and mixture sampling
ExpoCast (Wambaugh et al. 2013) provides exposure estimates, with measures of uncertainty,
for 1936 chemicals. Those exposure estimates were obtained using far-field, mass-balance
human exposure models (USEtox and RAIDAR). 
In ToxCast (11 December 2013 release), the Tox21-aromatase-inhibition assay is a cell-based
assay measuring CYP19A1 (aromatase) gene activity via a fluorescent protein reporter gene.
Chemicals acting on aromatase mRNA synthesis, degradation or translation, or on aromatase
itself  should  give  positive  results  in  this  assay  (Chen  et  al.  2015).  For  each  chemical  x
assayed, ToxCast provides the geometric mean and standard error for the parameter values
AC50,x,  Wx ,  Bx and  Tx of a Hill function fitted to the concentration-inhibition data (scaled
using the positive and negative controls' data):
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%Inhibition = Bx + (T x−Bx)
C x
W
AC50, x
W + C x
W (1)
In ToxCast, 1102 chemicals are identified as aromatase inhibitors by the Tox21-aromatase-
inhibition assay (on MCF-7 human breast cells)  with “some reasonable confidence in the
estimated parameter values”. Among those, 256 chemicals (matching either by CAS number
or chemical name) also had exposure estimates in ExpoCast. However, cytotoxicity has been
shown to induce many false positive results  in ToxCast  (Judson et  al.  2016).  Of the 256
chemicals mentioned above, we kept only the 86 which had an AC
90
 for aromatase inhibition
lower than their cytotoxicity AC
10
 (as measured by the ToxCast proliferation decrease assay
on  T47D  human  breast  cells).  The  virtual  mixtures  generated  included  all  of  those 86
chemicals.
Exposure modeling
ExpoCast  provided  the  molecular  mass,  geometric  mean,  and  lower  and  upper  95%
confidence limits of the exposure rate (mg/kg/day) for each chemical present in the randomly
generated mixtures. For constant exposure modeling over 10 months, we sampled a rate for
each chemical from the corresponding log-normal distribution, but with an SD scaled by the
square-root  of the number of days of exposure simulated (since a constant exposure rate
should be a time average level in that case) and converted it to µmole/kg/minute.
More realistic time-varying exposures over a two-year period were also modeled (similarly to
Bertail et al. 2010) using exposure windows of random length and intensity. We first sampled
the  number  n of  exposure  windows  for  each  chemical  in  the  mixture  from  a  scaled
exponential  distribution (with  a  rate  parameter  equal  to  5).  That  yielded on average 145
exposure events over two years (median: 100 events, 1st quartile: 40 events, 3rd quartile: 200
events).  The  n exposures'  start  and end times were sampled uniformly over the two-year
period. The exposure rate during each of the  n exposure windows was randomly sampled
from the log-normal distribution given by ExpoCast, with an SD scaled by the number of
days of the exposure window considered (or unscaled if the exposure lasted less than a day).
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To  get  a  lower  bound  on  the  effect  of  mixtures,  we  similarly  simulated  random  non-
overlapping exposures to  the 86 EDCs selected (i.e.,  each person was exposed to the 86
chemicals, in random order, at random times, but to only one chemical at a time).
Pharmacokinetics modeling
For each  chemical in each mixture, a one-compartment PK model was used to estimate its
internal concentration (in μM) at steady-state in the case of constant oral exposure or at any
point in time in the case of varying oral exposures. Steady-state internal concentrations for
chemical x were calculated as:
C x ,ss =
Fx⋅Ex
K e, x
, (2)
where Fx is the bioavailability of x (unitless), Ex its exposure rate (in µmol/kg/min, sampled
as indicated above), and Ke,x its total body clearance rate constant (in min
-1). A body density
of 1 was assumed.
For time-varying exposures, internal concentrations were obtained as a function of time by
numerical integration of the following differential  over a two-year period (with an initial
value set to zero):
∂C x
∂ t
= F x⋅Ex − K e, x⋅C x (3)
We used quantitative structure-activity relationships (QSAR) to obtain central estimates of Fx
and Ke,x for each of the 86 aromatase inhibitors considered. The robustness of the prediction
was evaluated by examining compounds from the training set similar to the target substances,
together with literature data and references.
Fx central estimates were obtained at several oral dose levels and were linearly interpolated
between dose levels as needed. Beyond the dose rates of 0.001 to 10 mg/day, the Fx value at
the closest bound was used).
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To  take  into  account  the  uncertainty  affecting  the  QSAR estimated  PK  parameters,  we
randomly sampled  F values from Beta distributions (naturally bounded between 0 and 1),
with parameters calculated so that the distribution modes corresponded to the interpolated
value of Fx, with a CV of 20% (for null Fx modes, a and b were set to 1 and 50, yielding a
median at 0.01, a 1st quartile at 0.006, and a 3rd quartile at 0.03, approximately). Ke,x values
were log-normally sampled with a geometric mean equal to the central estimates obtained by
QSAR and a geometric SD corresponding to a factor 3.
Ovarian cycle model
We adapted  the  menstrual  cycle  model  presented  by Chen and Ward  (2013).  The model
describes the inhibitory and stimulatory effects of hormones E2 and P4 on the hypothalamus-
pituitary axis in women (Figure 1). The equations and definitions of all parameters used in
the model are given in Methods S2 and Tables S3 and S4 of the Supplemental Material. In the
original model, E2 and P4 were assumed to be instantaneously in equilibrium between blood
and the ovaries. Instead, we described the kinetics of E2 and P4 by differential equations
(eqs. 15-19 in Methods S2). That modification had practically no impact on the time course
of the model variables during a normal cycle (equilibrium between blood and ovaries is fast,
as assumed by Chen and Ward), but it allowed us to coherently integrate the dynamic aspect
of estradiol synthesis inhibition by EDCs. The three additional parameters (blood and ovarian
volumes, ovarian blood flow) were obtained from the literature (Table S3).
An additional variable, the ratio of disrupted over basal E2 synthesis rate constants (EDCYP19),
was introduced to link the internal doses of chemicals in mixtures to aromatase inhibition.
EDCYP19 was calculated using Hill’s model, parametrized with the chemical-specific values
provided  by  ToxCast,  as  a  cumulative  product  of  remaining  activity  for  each  of  the  m
chemicals of the mixture considered:
EDCYP19 = ∏
x=1
x=m
(1− T x100 (AC50, xW i + C xW i)) (4)
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Figure 1. Regulatory pathways of the human menstrual cycle, as implemented in the model.
During the follicular phase (1: germ cells; 2: developing follicle; 3: mature follicle; 4:
ovulation; 5: corpus luteum formation; 6: corpus luteum degradation), negative feedback by
E2 reduces FSH secretion, leading to the selection of one follicle for ovulation. GnRH
secretion is promoted by E2 and inhibited by P4, inducing a LH peak and consecutive
ovulation. E2 is mainly produced by follicles and corpus luteum and P4 by corpus luteum.
For constant exposures, Cx was set to the steady-state internal concentrations Cx,ss. For time-
varying exposures,  Cx was computed by integration as explained above. The parameters  Bx
were set to zero because a positive inhibition with no dosage would not make sense. AC50,x,
Wx and  Tx values were randomly sampled using the mean and standard error provided by
ToxCast.  AC50,x was sampled from a log-normal distribution (its logarithm is actually the
ToxCast  fitted  value).  Wx and  Tx were  sampled  from  truncated  normal  distributions.
Truncation was from 0 to 10 for Wx (values beyond 10 would be found for some chemicals
for which Wx is poorly identified, but have no biological meaning). Truncation was from 0 to
100 for letrozole's Tx (the positive control). For the other chemicals, truncation was from 0 to
10000 over Tx for letrozole to properly rescale the ToxCast Tx values between 0 and 100.
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EDCYP19 was entered as an input to the ovarian cycle model, which was then solved to obtain
the time profile of its output variables over two years of simulated time. In case of constant
exposures,  we  computed  the  square-root  of  the  sum of  the  squared  Euclidean  distances
between a reference E2 concentration (EDCYP19 set at zero) and the perturbed concentrations
(at a fixed set of times) as a summary measure of disruption.
Software used
ACD/Labs Percepta platform modules “ACD/Oral Bioavailability” and “ACD/ PK Explorer”
were used for the prediction of oral bioavailability (F) and total body clearance rate constant
(Ke), respectively (see Methods S1, Table S1, Figures S2 and S3 in Supplemental Material).
GNU  MCSim v5.6.5  (www.gnu.org/software/mcsim)  (Bois  2009) was  used  to  build  the
ovarian cycle model. R v3.1.1 (www.R-project.org) (R Development Core Team 2013) with
packages  parallel,  deSolve and  EnvStats was  used  for  database  processing,  numerical
integration of the models, and graphics. 
RESULTS
Estimates of internal dose
The relationship between constant exposure rates and steady-state internal concentrations for
the 86 EDCs considered indicates that exposures ranged from 10-8 to 10-3 µmole/kg/ day and
the resulting steady-state internal concentrations ranged from 10-13 to 10-3 µM (Figure S4,
Supplemental  Material).  The  exposure rates  and pharmacokinetic  parameters  were Monte
Carlo sampled as explained above. For any single EDC, uncertainty is about a factor of 10 for
exposures and a factor of 1000 for the resulting internal concentrations.  For time-varying
exposures, Figure S5 (Supplemental Material) shows an example of a simulated random two-
year time course of internal concentration for lindane. Such profiles were obtained for each
chemical in each simulated mixture.
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Cycle model behavior
Our implementation of the ovarian cycle model proposed by Chen and Ward (2013) correctly
reproduces their results. Human data from McLachlan et al. (1990) and Welt et al. (1999) on
LH, FSH, E2 and P4 normal cycles are correctly simulated, except for McLachlan FSH data
for which the baseline levels are not well matched. There is a large intra- and inter-variability
in hormonal levels across women in those datasets (see Supplemental Material Figure S6).
We took the model simulated normal cycling of E2 as the “reference cycle” in the following.
Constant exposure scenarios result, at steady-state, in a constant level of aromatase inhibition.
In  that  case,  perturbation  depends  only  on  that  parameter  (according  to  the  model
assumptions) so the distance between the perturbed and reference cycles is a useful measure
of  effect  (see  Figure  2).  As  aromatase  inhibition  increases,  cycles  become  increasingly
perturbed and exhibit chaotic features (hence the misalignment of the points in Figure 2). At
5% inhibition  (95% of  normal  aromatase  activity),  cycles  are  shortened,  baseline  levels
change little, and peak levels either increase or decrease less than proportionally except for
LH. Basically, the regulations dampen the effect of perturbation. At about 10% inhibition, LH
peaks disappear after about five cycles and a major bifurcation in cycle patterns happens:
cycles are further shortened, and baseline levels are much increased (doubled for E2 and P4,
for example, even though E2 synthesis by aromatase is  decreased) and peak levels mostly
decreased; E2 distance to normal increases up to a maximum (Figure 2). At higher inhibition
levels the cycles dampen more and more to disappear completely between 30% and 40%
inhibition  levels  (see  Supplemental  Material  Figures  S7-S10).  Overall,  according  to  this
model,  having  less  than  10%  constant  inhibition  of  aromatase  activity  in  vivo leads  to
perturbations of the cycle, which is still under control and should be compatible with normal
reproductive function. Beyond 10% inhibition, an actual disruption of the system seems to
occur.
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Figure 2. Euclidean distance between an estradiol normal cycle and perturbed cycle as a
function of aromatase inhibition at steady-state. Distance is computed over two years based
on 7301 time points (one every 144 minutes).
Effect of single chemicals
We first simulated a million constant exposures to each of the 86 chemicals considered, taken
individually. In that case, despite accounting for uncertainty in exposure levels and dose-
response parameters, none of them induced more than 1% aromatase inhibition. Hence, none
of them alone was able to induce a significant disruption of the ovarian cycle. Figure 3 places
those chemicals on a map with the slope W of the Hill dose-response curve at AC50, and the
log-margin of exposure as coordinates. Margin of exposure was defined as the ratio of the
97.5  percentile  of  internal  concentrations  over  AC50.  The  log10-margins  of  the  chemicals
studied ranged from -10 to -1.8. That means that for all chemicals, the high-end of internal
exposure concentrations was at most 1% of  AC50. In that case, equation 1 shows that the
logarithm of aromatase inhibition is approximately the product of W times the log-margin of
exposure. The color background of the map codes for the resulting “risk index” (i.e., log
10
-
inhibitions) and ranges from less than -2 (1%) to about -80 (10-78 %), much too low to elicit
changes in ovarian cycles such as seen in Figure 2. Therefore, no effects can be expected
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from usual exposures to those chemicals when considered alone. Table 1 gives the list of the
10 chemicals for which individual risk is the highest.  Note that letrozole is the reference
chemical for the Tox21 aromatase inhibition assay, which is consistent with its high rank. The
others are found in therapeutic drugs, agrochemicals, food contaminants, consumer products,
etc.
Figure 3. Map of the aromatase inhibitors studied over a plane defined by dose-
response slope W and log-margin of exposure (see text). Colors vary linearly with
powers of 10 of aromatase inhibition resulting from W and margin of exposure
combinations, from red (10-2) to blue (10-80). For the chemicals-numbers correspondence
see Supplemental Material Table S1.
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Table 1: Top ranking chemicals according to their individual risk indices a. Those
chemicals are in the top left corner of Figure 3.
ExpoCast Name CAS number Risk Index a
Letrozole 112809-51-5 -2.99
Estrone 53-16-7 -3.41
Fulvestrant 129453-61-8 -4.30
Triflumizole 68694-11-1 -4.81
2,4,7,9-Tetramethyl-5-decyne-4,7-diol 126-86-3 -5.11
N-Methyl-2-pyrrolidone 872-50-4 -5.49
Rhodamine 6G 989-38-8 -5.51
Anastrozole 120511-73-1 -6.04
Fenvalerate 51630-58-1 -6.05
Imazalil 35554-44-0 -6.31
a Risk Index = W × log
10
(E
95
 / AC
50
), where E
95
 is the 95th percentile of the
exposure values sampled.
Effect of mixtures of chemicals
We generated one million hypothetical mixtures of the 86 aromatase inhibitors studied and
evaluated their global effect on E2 synthesis and resulting ovarian cycle disruption. Figure 4
shows a histogram of the resulting inhibition levels. Depending on the (random) composition
of the mixtures, and given the uncertainties on exposures and effect parameters, responses
range from zero to 100% inhibition, but on average are very high. Such inhibition levels may
lead to  perturbation  of  the  ovarian  cycle,  according to  the  model.  Real-life  exposures  to
chemicals are usually not at constant levels. We simulated time-varying exposures (see Figure
S5,  Supplemental  Material)  and the resulting effects  on aromatase inhibition and ovarian
cycle disruption. To define a lower bound on mixture effects, we first simulated fluctuating
EDCs'  exposure levels,  but  without  concomitant  exposures  to  them. Interactions  can still
occur  in that case because of storage in the body or because of persistent effects  on the
ovarian cycle. Figure 5 shows that only 0.3% of the exposures simulated caused more that
10% average aromatase inhibition. The maximum inhibition found was close to 50%. More
realistic exposure scenarios do not prohibit concomitant exposures. In that case (Figure 6),
the distribution of simulated time-averaged inhibitions is shifted toward higher effects and
average inhibitions higher than 20% are not uncommon (yet they do not reach the extreme
levels observed on Figure 4). 
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Figure 4. Histogram of the percent inhibition of estradiol (E2) synthesis by random mixtures
(N = 1 million) of 86 aromatase inhibitors, at constant exposure levels.
Since inhibition changes with time, the distances between normal and perturbed cycles do not
follow the pattern of Figure 2 (distances can be much larger) and the link between estradiol
inhibition and cycle disruption is harder to establish. Examination of the time-course of the
dominant follicle mass (F), for 1000 random simulations of mixtures of the 86 chemicals,
shows that  perturbed cycles typically  have a baseline shifted up (which may or may not
return to normal) and in irregular succession of peaks (corresponding to ovulation) (Figure 7).
The 1000 simulations examined can be classified into four groups. In group 1 (17% of the
samples), the cycles are practically normal with no baseline shifts and at most one or two
missing ovulations. In group 2 (73% of cases), baseline shifts are always present but without
major irregularities in ovulation. Group 3 (7% of cases) has systematic baseline shifts and
frequent or prolonged anovulations. Such cycling would clearly impair fertility. In group 4 (3
% of cases), disruption is catastrophic or total. Figure S11 (Supplementary Material) shows
the corresponding plots for E2 time courses. Judging by them, E2 profiles can have a shifted
baseline even in normal ovulation profiles, but otherwise the patterns are rather similar.
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Figure 5. Histogram of the percent inhibition of estradiol (E2) synthesis by random mixtures
(N = 1 million) of 86 aromatase inhibitors with time-varying non-concomitant exposures. For
visibility, the first histogram bar has been truncated (it represents about 990000 simulations).
Figure 6. Histogram of the percent inhibition of estradiol (E2) synthesis by random mixtures
(N = 1 million) of 86 aromatase inhibitors with time-varying exposures.
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Figure 7. Typical simulated time profiles of dominant follicle mass during time-varying
exposures to random mixtures of 86 aromatase inhibitors. Four classes (rows) of increasing
disruption are illustrated (see text). Left column: least disrupted profile in its class; Right
column: most disrupted. Responses range from regular ovulation (panel 1a) to complete
disruption (panel 4b).
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DISCUSSION
We linked ToxCast data and ExpoCast estimates of exposures to (mixtures of)  aromatase
inhibitors, and estimated their effects on the ovarian cycle in women. To our knowledge, this
is the first application of computational toxicology and high-throughput testing to assessing
the combined effect of exposures to a large number of EDCs.
Our  approach  is  predictive  and  we  had  to  make  many  assumptions  and  simplifications.
ToxCast and ExpoCast are still  incomplete and a full inventory of all the EDCs to which
women are exposed is not yet available. So, we were only able to look at a subset of the
potential EDCs. We used human exposure estimates from Wambaugh et al. (2013), who give
summary statistics for the distribution of exposures to individual chemicals. This allowed us
to  take  the  correspondingly  large  uncertainty  into  account  via  Monte  Carlo  simulations.
However,  we  cannot  differentiate  between  uncertainty  and  variability  in  those  exposure
estimates, and cannot identify subgroups of sensitive individuals. We cannot even focus on
women, our target population. More sophisticated exposure models (Isaacs et al. 2014) could
help in that respect, but they still  deal only with single chemicals and provide no data or
estimates about co-exposures. Depending on age, occupation, socioeconomic status, ethnicity,
and  health  condition,  we  are  exposed  to  different  cocktails  of  chemicals  in  our  diet,
workplace,  environment,  etc.  (Tornero-Velez  et  al.  2012).  We  modeled  co-exposures  by
random sampling, either at a constant level or more realistically with time-varying exposure
profiles and hence time-varying mixture complexity. That is still imperfect and we had to
make  guesses  about  the  distribution  of  number  of  exposure  windows,  for  example.  We
respected  the  distribution  of  population  exposure  levels  documented  by  ExpoCast,  but
lacking co-exposure information, our estimates might be lower or higher than reality. Efforts
are ongoing to collect relevant data; for example, in the European Total Diet Study (Vin et al.
2014).  An  analysis  of  such  data  (Traoré  et  al.  2016) shows  that  among  153  synthetic
chemicals  studied  in  seven  typical  French  diets  (food  associations),  three  of  them  are
aromatase  inhibitors  according to  ToxCast:  zearalenone,  triadimenol,  and lindane.  In  this
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regard,  mixtures of 86 or more aromatase inhibitors may seem unrealistic,  but only food
contaminants were studied in Traoré et al. (2016). 
We searched for the 86 selected aromatase inhibitors in a database of consumer products
marketed in the United States (Gabb and Blake 2016). Briefly, this database was constructed
by scraping product information from online retailers. It currently contains 53743 products.
Twelve of the 86 aromatase inhibitors were detected in 5701 products (representing 11% of
the products in the database).  [It is worth noting that none of the 86 aromatase inhibitors are
among the volatile fragrance chemicals detected in consumer products  (Steinemann 2015;
Steinemann  et  al.  2011),  so  aromatase  inhibitors  are  unlikely  to  be  hidden  in  generic
“fragrance” or “flavor” designations on consumer product labels.] Two-way combinations of
these chemicals were found in 220 products; and the three-way combination of carminic acid,
FD&C blue no. 1, and retinol was found in 3 products. This may not seem to point to a large
problem but it is an incomplete view of combinatorial exposure. Consider that 3660 out of
4501 makeup products (81%) in the database contain at least one of the aromatase inhibitors
considered (carminic acid, retinol, and artificial colors are common ingredients in makeup),
and  a  typical  consumer  uses  several  products  each  day,  possibly  even  several  makeup
products. This increases the likelihood of combined exposures. Also, no readily available data
address  associations  for all  near-  and far-field exposures  for the 86 aromatase inhibitors,
which are used in industrial or agricultural processes (18), consumer product formulations
(12), biocidal applications (38), and pharmaceutical drugs (18). These usage categories are
likely to be independent, so focusing on a few known associations would only give partial
answers  and underestimate  global  risk.  We are  striving  for  a  more  extensive  picture.  To
address  the  potential  overestimation  of  mixture  effects  when  generating  purely  random
associations,  we  present  the  results  of  a  very  optimistic  exposure  scenario  (with  no  co-
exposures at all). This gives a lower bound estimate: 0.3% of exposures would lead to more
than 10% average aromatase inhibition in women.
ToxCast aromatase inhibition data were obtained by exposing cells in vitro. We had no easy
way to assess the  in  vitro kinetics of the substances  assayed and reconstruction methods
(Armitage et al. 2014) require input data that we did not have. We assumed that the nominal
assay  concentrations  were  those  really  experienced  by  the  cells  and  that  equivalent
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extracellular concentrations  in vivo would lead to the same levels of aromatase inhibition.
That is a typical assumption but it is not necessarily correct (Coecke et al. 2012). To obtain
extracellular  concentrations  in  vivo,  we estimated  bioavailability  and total  clearance with
QSAR methods and input them in a simple one-compartment PK model with oral exposure
only  (even though inhalation or  dermal  exposures  might  be  more relevant).  Again,  more
sophisticated (PBPK) models and additional PK data would give more precise and accurate
predictions (El-Masri et al. 2016; Wambaugh et al. 2015).
On  the  effect  side,  we only  considered  chemicals  for  which  the  ToxCast  dose-response
parameters  were estimated with  reasonable confidence.  This is  a conservative choice and
additional chemicals would have been included if more relaxed criteria had been chosen (at
the price of lower confidence in the results). A concern with large databases such as ToxCast
is  the quality  assurance of  the data  provided.  Aromatase inhibition may not  be the most
sensitive toxicity endpoint, for example, or it may be due to a burst effect of cytotoxicity
(Judson et al.  2016). From the original set of 256 aromatase inhibitors for which we had
exposure estimates and ToxCast data, 170 were screened off based on cytotoxicity. Those
were mostly weak inhibitors (data not shown). For the screen, we kept only the 86 substances
which had an aromatase inhibition AC
90
 lower than their cytotoxicity AC
10
 – measured by the
ToxCast proliferation decrease assay on T47D human breast cells, a cell type similar to the
MCF-7 used by the aromatase inhibition assays (Aka and Lin 2012). We preferred that screen
to the omnibus z-score criterion,  which aggregates cytotoxicity results  from different cell
types and species.  For the remaining 86 substances,  we may still have downplayed other
types of toxicity. Cytotoxicity, by the way, is not a “negligible” endpoint, and an evaluation of
the cytotoxicity of mixtures would be interesting in its own right. 
The evidence provided by ToxCast is also not perfectly predictive of human  in vivo.  For
example, the Tox21 aromatase inhibition assay uses the MCF-7 breast cancer cell lines which
might not respond as normal ovary cells. In addition, our model of the ovarian cycle (Chen
and Ward 2013) describes only approximately the complex dynamic interactions between
ovarian follicular growth and hormonal homeostasis. The hypothalamus and pituitary gland
are treated as a single compartment and the description of the central hormonal controls is
simplified. More complex models have been proposed  (Hendrix et al.  2014) but they still
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make many assumptions and do not seem to offer dramatically better performance. Note also
that we treated the parameters of the ovarian cycle as constant, when in fact they are affected
by  both  uncertainty  and  variability  in  response  to  EDCs,  adding  to  the  tails  of  the
distributions  of  our  results.  However,  we  did  not  have  sufficient  information  to  define
statistical distributions for those parameters.
In  terms  of  results,  an  obvious  question  is  that  of  the  “bad”  actors,  i.e.,  the  chemicals
responsible for the predicted effects. The answer is provided by Figure 3 (and partially by the
top-ten  Table  1),  because  here  the  impact  of  individual  chemicals  on  aromatase  is  only
conditioned by internal dose and inhibition potency. Figure 3 is actually a useful prioritization
tool. It is rather simple to construct and does not require running the ovarian cycle (the PK
model is needed). However, it does not give an answer in terms of magnitude of effect at the
subject level. For that we need the whole body ovarian cycle model.
One of the consistent features of E2 cycle perturbation that we found is that the baseline
(inter-ovulation) levels of E2 tend to increase (to about twice the normal level) in response to
aromatase  inhibition  (which  implies  a  lower  rate  of  E2  synthesis  by  aromatase).  That
counterintuitive  feature  of  the  complex  cycle  dynamic  is  induced  by the  CNS feedback.
Passed a certain level of inhibition, the control of E2 still “works” (peaks are still observed)
but puts the baseline at a higher value. We do not have confirmation that this is the case in
women exposed to EDCs, but that would be interesting information and a potential biomarker
of effects. Note also that we lack good measures of perturbation for such complex systems.
We used visual  inspection to classify cycles for 1000 time-varying exposures (Figure 7).
Perturbation analysis of more cycles would require more sophisticated tools.  Finally, many
other perturbation pathways exist for ovarian cycle disruption which were not accounted for
(e.g., actions mediated by the androgen or estrogen receptors). The simplicity of our model
also  precludes  investigation  of  synergistic  or  antagonistic  effects  that  could  be  due  to
metabolic or toxicodynamic interactions (Cheng and Bois 2011).
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CONCLUSIONS
High-throughput  data  collection  requires  high-throughput  analysis,  extrapolation,  and
decision  tools  if  we  want  to  avoid  a  bottleneck  and  accumulation  of  unused  data.  We
developed such a tool, making use of our increasing understanding of toxicity mechanisms.
This exercise in prediction points to large data gaps. Our knowledge of exposure to actual
mixtures  is  minimal,  except  in  a  few cases  (tar,  tobacco smoke,  etc.)  For  the  chemicals
studied here, quantitative knowledge of their routes of exposure and PK parameters is also
lacking. Our knowledge of endocrine disruption mechanisms is still in its infancy. We should
probably check, for example, the inhibition potential of the 86 substances studied here with
better tests and a better characterization of the in vitro fate of the chemicals. At least we now
have a prioritized list and some reason to deepen our investigations. We should also research
relevant  human biomarkers of exposure or effects  for validation of the results  and better
actions. 
The  basic  assumption  of  regulatory  practice  and  most  risk  assessments  is  that  keeping
individual chemicals under control with reasonable safety factors will keep their joint effects
at bay. That may not be the case. Some women have various levels of ovarian dysfunction
that  can  be  caused  by  various  internal  and  external  factors.  Environmental  chemical
exposures add onto that background (National Research Council 2009; Zeise et al. 2013). We
found that even though individual chemicals are probably “safe” as used now, their  joint
effects,  when they exceed a  few dozens  in  number,  can lead to  severe  disruption of  the
ovarian cycle in women in a sizable number of cases. Obviously, this is no definite proof that
some fertility problems can be caused by real-life exposures to EDCs. Still, risk assessment
practice and regulations should start thinking of the problem of mixtures not as an unsolvable
one,  but  as  needing a  clearly  laid  out  research  agenda.  In  the  case  in  point,  the  simple
graphical  map  of  internal  dose  and  potency  we  propose  could  already  be  used  for
prioritization. Given the magnitude range of the predicted effects on ovarian cycling, while
waiting for confirmation of our results, a cautionary attitude should be adopted.
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Figure S1: Computational workflow.
Figure S1. Computational workflow. Each box represents a task to be executed or a result obtained
and arrows represent either data flow or execution dependencies between different tasks. Random
mixtures of chemicals are sampled from ExpoCast. The kinetics of each chemical in the human
body are computed using a one-compartment PK model. The resulting aromatase inhibition is
computed from ToxCast dose-response information. The impact of that inhibition on the menstrual
cycle is estimated using an ovarian cycle model adapted from Chen and Ward (2013).
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Methods S1: PK modules of ACD/Labs.
The  ACD/Oral  Bioavailability  module uses  a  combination  of  probabilistic  and  mechanistic
models  to  predict  oral  bioavailability  based  on  a  dataset  of  oral  bioavailability  data  for  788
substances. The module predicts the fraction of the specified dose that reaches systemic circulation
after oral administration (F), with the possibility to explore dose-dependence of F. The default oral
dose  used  in  calculations  is  50 mg.  The mathematical  model  used  for  simulations  in  the  Oral
Bioavailability (and PK Explorer) modules is based on differential equations that consider solubility
in the gastrointestinal tract, passive-absorption in jejunum, elimination (total body clearance), and
volume of distribution. Simulations performed with the Oral Bioavailability module ignore first-
pass metabolism in liver and gut. Quantitative F values are calculated as a ratio of AUCs after oral
and  intravenous  administration.  A number  of  endpoints  affecting  oral  bioavailability  are  also
predicted, including solubility (dose/solubility ratio), stability in acidic media, intestinal membrane
permeability by passive or active transport (with a summary of transporters where relevant),  P-gp
efflux  (multi-drug transporter  P-glycoprotein)  and  first  pass  metabolism  in  the  liver.  For  the
majority of these parameters, ACD/Labs Percepta allows the user to assesses the confidence in the
predicted result by means of reliability index and/or displaying similar structures from the training
set along with their experimental test results.  Since the bioavailability predictions are based on a
mechanistic simulation model rather that statistical fitting to data, the validation procedure was not
based on a conventional training/test set approach. Instead, a set of clinical fraction absorbed (fa)
data together with dosage information for 28 drugs reported by Parrot and Lavé (2002) was used for
validation purposes. The model performance was assessed qualitatively, by evaluating the accuracy
of three-class classification (i.e., “low” for fa  ≤ 33%, “moderate” for 33% < fa  < 66%, “high” for fa
≥ 66%), and quantitatively, using the Residual Mean Square Error statistic and visual inspection of
the correlation between observed and predicted fa  values for the drugs considered. For the majority
of drugs, calculated values were in good agreement with clinical data, resulting in 80% correct
classification and an RMSE equal to 17%.
ACD/PK Explorer is a tool for exploring pharmacokinetic relationships (e.g., F–Dose relationship)
using physico-chemical parameters as inputs for calculations.  Total body clearance rate constant
(Ke) is among the required parameters of our PK model. Ke was estimated using a set of fragmental
ionization  class  specific  models.  Hydrophobicity  (logP)  and  ionization  (pKa)  are  the  principal
descriptors for the prediction of Ke. These descriptors were calculated in silico. Technical details on
those models and equations are not available since they are proprietary information of ACD/Labs.
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Table S1: Predictions of bioavailability (F) and total body clearance rate constant (Ke). The ACD/Labs Percepta Oral Bioavailability module was 
used for predictions of oral F values. F predictions depend on oral dose and are given for an array of doses. The module ACD/ PK Explorer was 
used for the prediction of Ke values.
ID CAS
F 
(0.001 mg)
F 
(0.01 mg)
F 
(0.1 mg)
F 
(1 mg)
F
(5 mg)
F 
(10 mg)
F 
(50 mg)
F 
(100 mg)
F 
(500 mg)
F 
(1000 mg)
Ke (min
-1)
1 101-20-2 0.2805 0.2804 0.2798 0.2739 0.2505 0.2269 0.1342 0.0919 0.0295 0.0168 0.00083
2 101-80-4 0.9760 0.9760 0.9760 0.9759 0.9754 0.9748 0.9661 0.9486 0.5863 0.3625 0.002
3 112281-77-3 0.9907 0.9907 0.9907 0.9907 0.9903 0.9899 0.9826 0.9575 0.5201 0.3202 0.0011
4 112809-51-5 0.9919 0.9919 0.9919 0.9919 0.9917 0.9915 0.9880 0.9771 0.6065 0.3808 0.00041
5 114369-43-6 0.7271 0.7270 0.7261 0.7175 0.6807 0.6385 0.4214 0.2983 0.0986 0.0566 0.0011
6 115-39-9 0.2164 0.2164 0.2158 0.2104 0.1897 0.1694 0.0956 0.0644 0.0201 0.0114 0.00087
7 116255-48-2 0.9884 0.9884 0.9884 0.9882 0.9872 0.9856 0.9580 0.8774 0.3949 0.2374 0.0011
8 117-39-5 0.9533 0.9533 0.9533 0.9532 0.9528 0.9521 0.9429 0.9247 0.5982 0.3723 0.0062
9 1192-52-5 0.9942 0.9942 0.9942 0.9942 0.9942 0.9942 0.9942 0.9942 0.9938 0.9933 0.0015
10 120511-73-1 0.9916 0.9916 0.9916 0.9916 0.9915 0.9915 0.9910 0.9901 0.9455 0.7218 0.0009
11 125-84-8 0.9936 0.9936 0.9936 0.9936 0.9936 0.9936 0.9935 0.9932 0.9899 0.9812 0.0019
12 126-72-7 0.9908 0.9908 0.9908 0.9907 0.9904 0.9899 0.9826 0.9586 0.5198 0.3193 0.0012
13 126-86-3 0.9938 0.9938 0.9938 0.9938 0.9937 0.9935 0.9915 0.9862 0.6964 0.4480 0.0017
14 1260-17-9 0.0078 0.0078 0.0078 0.0078 0.0078 0.0078 0.0078 0.0078 0.0078 0.0078 0.0049
15 129-17-9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0071
16 129453-61-8 0.0067 0.0067 0.0066 0.0064 0.0056 0.0049 0.0026 0.0017 0.0005 0.0003 0.0002
17 131341-86-1 0.9393 0.9393 0.9390 0.9360 0.9223 0.9039 0.7408 0.5798 0.2155 0.1264 0.0002
18 13171-00-1 0.9836 0.9836 0.9835 0.9830 0.9802 0.9759 0.9089 0.7791 0.3177 0.1886 0.0012
19 131860-33-8 0.9603 0.9603 0.9601 0.9581 0.9481 0.9337 0.7802 0.6097 0.2225 0.1298 0.00068
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ID CAS
F 
(0.001 mg)
F 
(0.01 mg)
F 
(0.1 mg)
F 
(1 mg)
F
(5 mg)
F 
(10 mg)
F 
(50 mg)
F 
(100 mg)
F 
(500 mg)
F 
(1000 mg)
Ke (min
-1)
20 13292-46-1 0.1755 0.1755 0.1755 0.1755 0.1755 0.1755 0.1755 0.1755 0.1754 0.1713 0.0019
21 133-06-2 0.8723 0.8723 0.8717 0.8665 0.8427 0.8128 0.6083 0.4543 0.1600 0.0930 0.0017
22 133-07-3 0.5715 0.5714 0.5705 0.5623 0.5282 0.4910 0.3167 0.2236 0.0742 0.0427 0.0015
23 133855-98-8 0.9064 0.9064 0.9059 0.9016 0.8814 0.8551 0.6557 0.4932 0.1743 0.1012 0.00075
24 137-26-8 0.9764 0.9764 0.9763 0.9750 0.9690 0.9603 0.8526 0.7011 0.2741 0.1619 0.0022
25 137-30-4 0.8689 0.8689 0.8689 0.8689 0.8689 0.8689 0.8689 0.8689 0.8689 0.8689 0.0032
26 14233-37-5 0.8501 0.8500 0.8494 0.8430 0.8143 0.7789 0.5556 0.4044 0.1376 0.0794 0.0014
27 15299-99-7 0.9827 0.9827 0.9826 0.9819 0.9785 0.9734 0.8969 0.7597 0.3053 0.1809 0.0014
28 155990-20-8 0.9920 0.9920 0.9920 0.9920 0.9920 0.9920 0.9920 0.9920 0.9919 0.9915 0.0013
29 15972-60-8 0.9952 0.9952 0.9952 0.9952 0.9952 0.9952 0.9950 0.9948 0.9901 0.9624 0.0019
30 16423-68-0 0.0002 0.0002 0.0002 0.0001 0.0001 0.0001 0.0001 0.0000 0.0000 0.0000 0.00065
31 175013-18-0 0.9892 0.9892 0.9892 0.9890 0.9882 0.9870 0.9656 0.8972 0.4116 0.2477 0.0012
32 17924-92-4 0.9958 0.9958 0.9958 0.9958 0.9958 0.9958 0.9953 0.9943 0.9495 0.7248 0.0022
33 1918-02-1 66.39 66.39 66.39 66.39 66.39 66.39 66.39 66.39 66.39 66.39 0.0025
34 199171-88-5 0.9916 0.9916 0.9916 0.9916 0.9916 0.9916 0.9913 0.9909 0.9811 0.9148 0.00099
35 2310-17-0 0.7593 0.7592 0.7584 0.7503 0.7153 0.6745 0.4547 0.3245 0.1083 0.0623 0.0014
36 2312-35-8 0.8301 0.8301 0.8294 0.8223 0.7913 0.7535 0.5266 0.3800 0.1280 0.0737 0.0013
37 2353-45-9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0047
38 24169-02-6 0.6276 0.6275 0.6266 0.6173 0.5789 0.5366 0.3397 0.2372 0.0773 0.0442 0.00089
39 2425-06-1 0.5641 0.5641 0.5632 0.5544 0.5186 0.4797 0.3031 0.2121 0.0695 0.0398 0.0016
40 29091-21-2 0.2182 0.2182 0.2177 0.2127 0.1932 0.1739 0.1007 0.0685 0.0218 0.0124 0.00054
41 30399-84-9 0.9043 0.9042 0.9037 0.8990 0.8772 0.8488 0.6383 0.4740 0.1645 0.0952 0.0011
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ID CAS
F 
(0.001 mg)
F 
(0.01 mg)
F 
(0.1 mg)
F 
(1 mg)
F
(5 mg)
F 
(10 mg)
F 
(50 mg)
F 
(100 mg)
F 
(500 mg)
F 
(1000 mg)
Ke (min
-1)
42 311-45-5 0.9965 0.9965 0.9965 0.9965 0.9965 0.9965 0.9965 0.9964 0.9957 0.9940 0.0023
43 35554-44-0 0.9924 0.9924 0.9924 0.9924 0.9924 0.9923 0.9916 0.9903 0.8887 0.6276 0.0012
44 3844-45-9 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.007
45 43121-43-3 0.9919 0.9919 0.9919 0.9918 0.9917 0.9915 0.9889 0.9819 0.6581 0.4188 0.0012
46 49562-28-9 0.9326 0.9326 0.9322 0.9286 0.9116 0.8886 0.6955 0.5259 0.1858 0.1079 0.0016
47 50-41-9 0.9197 0.9197 0.9193 0.9151 0.8954 0.8692 0.6612 0.4919 0.1704 0.0986 0.00014
48 50594-66-6 0.6879 0.6878 0.6868 0.6771 0.6361 0.5904 0.3727 0.2590 0.0836 0.0477 0.00064
49 51630-58-1 0.0101 0.0101 0.0100 0.0098 0.0087 0.0077 0.0042 0.0028 0.0009 0.0005 0.0014
50 52-01-7 0.9256 0.9255 0.9251 0.9209 0.9011 0.8746 0.6651 0.4948 0.1714 0.0991 0.0027
51 520-18-3 0.9892 0.9892 0.9892 0.9892 0.9890 0.9888 0.9865 0.9819 0.8086 0.5408 0.0015
52 521-18-6 0.9647 0.9647 0.9645 0.9624 0.9521 0.9375 0.7852 0.6166 0.2272 0.1328 0.0036
53 53-16-7 0.9600 0.9600 0.9598 0.9578 0.9480 0.9342 0.7886 0.6236 0.2321 0.1360 0.0012
54 55219-65-3 0.9917 0.9917 0.9917 0.9917 0.9914 0.9910 0.9858 0.9684 0.5578 0.3462 0.0013
55 57-63-6 0.8500 0.8500 0.8493 0.8430 0.8149 0.7801 0.5593 0.4083 0.1395 0.0806 0.0011
56 577-11-7 0.8287 0.8286 0.8278 0.8198 0.7841 0.7411 0.4968 0.3509 0.1149 0.0658 0.0055
57 58-14-0 0.9688 0.9687 0.9686 0.9672 0.9600 0.9488 0.7915 0.6000 0.2057 0.1184 0.0014
58 58-89-9 0.9227 0.9227 0.9223 0.9188 0.9024 0.8808 0.7044 0.5441 0.1994 0.1167 0.0018
59 60168-88-9 0.8674 0.8673 0.8667 0.8610 0.8352 0.8027 0.5871 0.4324 0.1493 0.0864 0.0011
60 60-57-1 0.3142 0.3142 0.3135 0.3071 0.2819 0.2562 0.1532 0.1054 0.0339 0.0194 0.0012
61 62924-70-3 0.3046 0.3045 0.3038 0.2971 0.2707 0.2442 0.1422 0.0968 0.0307 0.0175 0.00024
62 633-96-5 0.7686 0.7686 0.7686 0.7686 0.7686 0.7686 0.7684 0.7681 0.7457 0.6995 0.0027
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ID CAS
F 
(0.001 mg)
F 
(0.01 mg)
F 
(0.1 mg)
F 
(1 mg)
F
(5 mg)
F 
(10 mg)
F 
(50 mg)
F 
(100 mg)
F 
(500 mg)
F 
(1000 mg)
Ke (min
-1)
63 643-79-8 0.9938 0.9938 0.9938 0.9938 0.9938 0.9938 0.9938 0.9938 0.9934 0.9929 0.0014
64 6459-94-5 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00093
65 6610-29-3 0.4977 0.4977 0.4977 0.4977 0.4977 0.4977 0.4977 0.4977 0.4953 0.4840 0.0024
66 6625-46-3 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0001 0.0034
67 67-20-9 0.9912 0.9912 0.9912 0.9912 0.9911 0.9910 0.9898 0.9875 0.9150 0.6701 0.0016
68 67747-09-5 0.9904 0.9904 0.9903 0.9902 0.9896 0.9888 0.9742 0.9245 0.4481 0.2716 0.0013
69 68-26-8 0.9807 0.9807 0.9806 0.9799 0.9762 0.9706 0.8870 0.7427 0.2928 0.1729 0.0011
70 68694-11-1 0.9918 0.9918 0.9918 0.9918 0.9917 0.9916 0.9899 0.9856 0.7227 0.4689 0.00044
71 79241-46-6 0.9150 0.9150 0.9145 0.9103 0.8906 0.8646 0.6624 0.4965 0.1742 0.1010 0.0011
72 84-61-7 0.9670 0.9670 0.9668 0.9648 0.9553 0.9415 0.7935 0.6247 0.2304 0.1347 0.0029
73 85509-19-9 0.9813 0.9813 0.9812 0.9805 0.9771 0.9718 0.8933 0.7539 0.3011 0.1782 0.00051
74 86-50-0 0.9902 0.9902 0.9902 0.9899 0.9883 0.9860 0.9459 0.8454 0.3659 0.2190 0.002
75 872-50-4 0.9959 0.9959 0.9959 0.9959 0.9959 0.9959 0.9959 0.9959 0.9959 0.9959 0.0022
76 87392-12-9 0.9951 0.9951 0.9951 0.9951 0.9951 0.9951 0.9948 0.9944 0.9835 0.8928 0.0019
77 87674-68-8 0.9960 0.9960 0.9960 0.9960 0.9960 0.9960 0.9959 0.9959 0.9952 0.9936 0.0021
78 88-58-4 0.9925 0.9925 0.9925 0.9924 0.9924 0.9923 0.9916 0.9901 0.8756 0.6122 0.0012
79 88671-89-0 0.9916 0.9916 0.9916 0.9914 0.9905 0.9892 0.9648 0.8909 0.4072 0.2453 0.0019
80 88-72-2 0.9955 0.9955 0.9955 0.9955 0.9955 0.9955 0.9954 0.9952 0.9906 0.9465 0.0019
81 88-85-7 0.9950 0.9950 0.9950 0.9950 0.9950 0.9950 0.9950 0.9950 0.9950 0.9950 0.002
82 941-69-5 0.9955 0.9955 0.9955 0.9955 0.9955 0.9955 0.9955 0.9954 0.9950 0.9943 0.0019
83 94361-06-5 0.9921 0.9921 0.9921 0.9921 0.9920 0.9918 0.9901 0.9861 0.7296 0.4747 0.0019
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ID CAS
F 
(0.001 mg)
F 
(0.01 mg)
F 
(0.1 mg)
F 
(1 mg)
F
(5 mg)
F 
(10 mg)
F 
(50 mg)
F 
(100 mg)
F 
(500 mg)
F 
(1000 mg)
Ke (min
-1)
84 97-77-8 0.8355 0.8354 0.8347 0.8281 0.7985 0.7624 0.5412 0.3939 0.1343 0.0775 0.0024
85 98-51-1 0.9778 0.9778 0.9777 0.9768 0.9724 0.9661 0.8818 0.7463 0.3045 0.1811 0.0024
86 989-38-8 0.9518 0.9518 0.9515 0.9488 0.9359 0.9175 0.7391 0.5641 0.2002 0.1162 0.00041
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Figure S2: Bioavailabilities as predicted by the ACD/Labs software for each of 86 EDC.
Figure S2: Bioavailability as predicted by ACD/Labs for each of 86 chemicals. The blue and red
dots show respectively  the bioavailability for oral administration of 0.001 mg and 1000 mg of each
chemical.
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Figure S3: Histogram of the half-life of each of the 86 EDC.
Figure S3: Histogram of the half life of each of the 86 chemicals, calculated from the total body
clearance rate constant predicted by ACD/Labs. 
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Figure S4: Internal concentration vs. exposure rate for of each of the 86 EDC studied.
Figure S4: Steady-state internal concentrations of the 86 chemicals studied as a function of
exposure levels. Exposures and pharmacokinetic parameters were randomly sampled 10000 times
for each chemical (see text), resulting in visible spread. Results for two of the chemicals are
highlighted (anastrozole in blue and 4,4'-oxydianiline in red). 
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Figure S5: Example of a random internal exposure profile.
Figure S5: Example of a random internal exposure profile (for lindane). Exposure times and rates
were Monte Carlo sampled. Internal exposure as a function of time was obtained by numerical
integration of the one-compartment PK model. 
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Methods S2: Menstrual cycle model equations.
The equations of the menstrual cycle are adapted from Chen and Ward (2013), as indicated.
The differential equation for the dominant follicle mass (F) is a function of a background growth 
rate, a growth rate component stimulated by FSH according to Hill's model, and a degradation rate 
under LH control, also according to Hill's model:
∂F
∂ t
= γF +
βF⋅F⋅FSH
m6
ECFSH , F
m6 + FSH m6
−
γF,R⋅F
2⋅LH m7
ECLH , F
m7 + LH m7
(1)
The ruptured follicle or scar mass (R) is formed from F degradation, with first and converted to 
corpus luteum (C):
∂R
∂ t
=
γF,R⋅F
2⋅LH m7
EC LH ,F
m7 + LH m7
− γR,C⋅R (2)
The differential equation for corpus luteum mass is a function of its formation rate from R, and first 
order degradation:
∂C
∂ t = γR,C⋅R − δC⋅C
(3)
The initial quantities of estradiol (E2, in nanograms) and progesterone (P4, in nanomoles) in blood 
and ovaries are given by:
QE2 , b(t=0) = 60 ⋅ V blood (4)
QP4 , b(t=0) = 10 ⋅ V blood (5)
QE2 , o(t=0) = 4000 ⋅ V ovary (6)
QP4 , o(t=0) = 1200 ⋅ V ovary (7)
The concentration of E2 (nanograms/L) and P4 (nanomoles/L) in blood and ovaries are:
CE2 ,b = QE2 , b / V blood (8)
CE2 , o = QE2 , o / V ovary (9)
CP4 ,b = QP4 , b / V blood (10)
CP4 ,o = QP4 , o / V ovary (11)
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GnRH (arbitrary units) is promoted by blood E2, and inhibited by blood P4, according to Hill's 
models:
Gn =
E2b
m1
EC E2 , Gn
m1 +E2 b
m1
⋅
ECP4 ,Gn
m2
ECP4 ,Gn
m2 +P4b
m2
(12)
The blood FSH concentration (in μg/L) in under positive control by past values of GnRH (τ
FSH
 days 
before) and negative control by current E2, according to Hill's models:
FSH = (FSH min + (FSH max−FSH min)⋅Gn(t−τFSH )
m3
ECGnFSH
m3 + Gn(t−τFSH )
m3 )⋅ ECE2FSH
m4
ECE2 FSH
m4 +E2b
m4
(13)
The blood LH concentration (in μg/L) in under positive control by past values of GnRH (τ
LH
 days 
before), according to Hill's model:
LH = LH min+
(LHmax−LH min)⋅Gn(t−τLH)
m5
ECGnLH
m5 + Gn(t−τLH)
m5
(14)
The differential equation for E2 quantity in blood is a function of transport to and from the ovaries, 
extra-ovarian production, and elimination rates:
∂QE 2,b
∂ t
= Fovary(CE2 , o − CE2 , b) + KpE2⋅βE2−KeE2⋅CE2 ,b (15)
The differential equation for E2 quantity in the ovaries is as a function of its transport to and from 
blood, and its follicular and luteal production, which can be both affected by endocrine disruption 
(ED):
∂QE2 ,o
∂ t
= EDcyp19⋅KpE2⋅(βE2 F⋅F + βE2C⋅C) − Fovary(CE2 , o − C E2 ,b) (16)
The differential equation for the quantity of P4 in blood is a function of its transport to and from the
ovaries, extra-ovarian production, and elimination rates:
∂QP4 , b
∂ t
= Fovary (CP4 , o − CP4 , b) + KpP4⋅βP4 − KeP4⋅CP4 , b (17)
The differential equation for the quantity of P4 in the ovaries is a function of transport to and from 
blood, and luteal production:
∂QP4 , o
∂ t
= KpP4⋅βP4C⋅C − Fovary (CP4 , o − CP4 , b) (19)
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Table S3: Menstrual cycle parameter values. Value are from Chen and Ward (2013), except were 
indicated.
Parameter Symbol Value (units)
Ratio of disrupted over control E2 synthesis  EDCYP19 - a
Time delay for GnRH control of FSH τFSH 1 (day)
Time delay for GnRH control of LH τLH 1.4 (day)
Baseline E2 concentration βE2 0.1 (ng/L)
Follicular contribution to E2 synthesis βE2,F 0.48 (ng/L/mass of F)
Luteal contribution to E2 synthesis βE2,C 0.36 (ng/L/mass of F)
E2 clearance from blood Ke,E2 1600 (L/day)
E2 synthesis scale factor Kp,E2 1600 (L/day)
Baseline P4 concentration βP4 0  (nmol/L)
Luteal contribution to P4 synthesis ΒP4,C 0.12  (nmol/L/mass of C)
P4 clearance from blood Ke,P4 3621 (L/day) b
P4 synthesis scale factor Kp,P4 3621 (L/day)
E2 EC50 for GnRH secretion promotion ECE2,Gn 185 (ng/L)
E2 Hill exponent for GnRH secretion m1 2 (unitless)
P4 EC50 for GnRH secretion inhibition ECP4,Gn 10  (nmol/L)
P4 Hill exponent for GnRH secretion inhibition m2 2 (unitless)
GnRH EC50 for FSH secretion promotion ECGn,FSH 0.453 (arbitrary units)
GnRH Hill exponent for FSH secretion promotion m3 2 (unitless)
E2 EC50 for FSH secretion inhibition ECE2,FSH 432 (ng/L)
E2 Hill exponent for FSH secretion inhibition m4 4 (unitless)
Minimum FSH concentration FSHmin 28.5 (μg/L)
Maximum FSH concentration FSHmax 500 (μg/L)
GnRH EC50 for LH release ECGn,LH 0.447 (arbitrary units)
GnRH Hill exponent for LH release m5 10 (unitless)
Minimum LH concentration LHmin 36.4 (μg/L)
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Maximum LH concentration LHmax 676 (μg/L)
Baseline follicle growth rate γF 0 (arbitrary units/day)
FSH EC50 for follicle growth stimulation ECFSH,F 150 (μg/L)
FSH Hill exponent for follicle growth stimulation m6 2 (unitless)
FSH enhanced follicle growth stimulation rate constant βF 2.1 (1/day)
LH EC50 for follicle rupture ECLH,F 325 (μg/L)
LH Hill exponent for follicle rupture m7 2 (unitless)
Follicle rupture rate constant per unit follicle mass γF,R 0.06 (1/day/arbitrary units)
R to C conversion rate constant γR,C 0.285 (1/day)
Corpus luteum decay rate constant δC 0.345 (1/day)
Blood volume Vblood 4.1 (L) c
Ovaries volume Vovary 0.2 (L) c
Ovaries blood flow Fovary 30 (L/day) c
a The value of this parameter depends on exposure to endocrine disrupting chemicals.
b Little et al. (1966).
c International Commission on Radiological Protection (ICRP) (2002).
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Table S4: Menstrual cycle initial state variables' values.
State variable Symbol Value (units)
Dominant follicle mass F 79.48 (arbitrary units)
Ruptured follicle (scar) mass R 20.23 (arbitrary units)
Corpus luteum mass C 33.35 (arbitrary units)
Quantity of estradiol in blood QE2,b 206.1 (ng)
Quantity of estradiol in ovaries QE2,o 545.1 (ng)
Quantity of progesterone in blood QP4,b 16.43 (nmol)
Quantity of progesterone in ovaries QP4,o 97.53 (nmol)
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Figure S6: Simulation of normal ovarian cycling and comparison to data.
Figure S6: Model simulated time course of LH, FSH, E2 and P4 during normal human ovarian
cycles (red lines). The model equations and parameter values used are given in Methods S2 and
Tables S3 and S4 above. Data are overlaid as points: purple circles from McLachlan et al. (1990,
Fig. 1); gray triangles from Welt et al. (1999). The LH data points from Welt et al. were rescaled so
that their baseline values match with those of McLachlan et al. The same rescaling factor was
applied to Welt et al. FSH data.
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Figures S7-S10: Simulation of normal and perturbed ovarian cycling.
Figure S7: Simulated time course of all model variables during normal ovarian cycles (parameter
EDCYP19 set to 1, black lines) and with a 5% constant inhibition of aromatase (parameter EDCYP19 set
to 0.95). The model equations and parameter values used are given in Methods S2 and Tables S3
and S4 above. LH and FSH units are in μg/L. GnRH units are arbitrary, the units of the other
variables are given in Table S4 above. The perturbed cycle differs only slightly from normal.
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Figure S8: Simulated time course of all model variables during normal ovarian cycles (parameter
EDCYP19 set to 1, black lines) and with A 10% constant inhibition of aromatase (parameter EDCYP19
set to 0.9). The model equations and parameter values used are given in Methods S2 and Tables S3
and S4 above. LH and FSH units are in μg/L. GnRH units are arbitrary, the units of the other
variables are given in Table S4 above. LH peaks disappear rapidly and the systems bifurcates to a
new solution.
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Figure S9: Simulated time course of all model variables during normal ovarian cycles (parameter
EDCYP19 set to 1, black lines) and with A 20% constant inhibition of aromatase (parameter EDCYP19
set to 0.8). The model equations and parameter values used are given in Methods S2 and Tables S3
and S4 above. LH and FSH units are in μg/L. GnRH units are arbitrary, the units of the other
variables are given in Table S4 above. The cycle is profoundly disrupted.
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Figure S10: Simulated time course of all model variables during normal ovarian cycles (parameter
EDCYP19 set to 1, black lines) and with A 40% constant inhibition of aromatase (parameter EDCYP19
set to 0.6). The model equations and parameter values used are given in Methods S2 and Tables S3
and S4 above. LH and FSH units are in μg/L. GnRH units are arbitrary, the units of the other
variables are given in Table S4 above. The cycle is totally disrupted.
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Figure S11: Simulation of estradiol time profiles during time-varying exposures to 86 EDCs.
Figure S11: Typical simulated time profiles of estradiol concentration during time-varying
exposures to random mixtures of 86 aromatase inhibitors. Four classes (rows) of increasing
disruption are illustrated (see main text). Left column: least disrupted profile in its class; Right
column: most disrupted. Panel 1a shows a practically normal profile with regular ovulation peaks.
Panel 4b shows complete disruption.
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